Prognostic value of 18F-FDG PET/CT imaging and VEGF expression in non-small cell lung cancer
ZHOU Xiao-liang1, DENG Hao-yu2, WU Wu-lin1, MO Yi3, LOU Ming-wu1
1. Department of Radiology, Longgang District Central Hospital of Shenzhen, Shenzhen College of Clinical Medicine,
Guangzhou University of Chinese Medicine, Shenzhen Guangdong 518116, China;
2. Department of Nuclear Medicine, Xiangya Hospital of Central South University, Changsha 410008, China;
3. Department of PET Center, Tumor Hospital of Hunan Province, Changsha 410013, China
Abstract：Objective: To evaluate the value of PET/CT imaging and VEGF expression in predicting postoperative outcome of non-small cell lung cancer. Methods: Forty patients with non-small cell lung cancer underwent preoperative whole-body PET/CT imaging examination. Tissue samples were collected for VEGF immunohistochemical analysis. Mattern’s semi-quantitative analysis was used to evaluate the VEGF expression in the tumor tissue. According to the clinical and pathological characteristics, the differences of SUVmax and VEGF expression scores among different groups were compared and their correlations were analyzed. Results: SUVmax and VEGF expression scores were significantly correlated with tumor size and differentiation (P<0.05). SUVmax and VEGF expression scores in lung cancer were significantly correlated(r=0.394, P<0.01). Kaplan-Meier analysis showed that SUVmax and VEGF scores were the influencing factors of patient survival. The disease-free survival time of SUVmax ≤7.3 was longer than >7.3 groups(P<0.05). The disease-free survival time of VEGF score ≤3 was also higher than that of VEGF score >3 groups. Cox multivariate analysis showed that SUVmax and TNM staging were independent prognostic factors for patient survival. Conclusion: SUVmax and VEGF expression are related to tumor differentiation and recurrence. SUVmax and VEGF expression scores can be considered as index to evaluate the prognosis of patients.
周晓亮1，邓豪余2，吴武林1，莫 逸3，娄明武1. 18F-FDG PET/CT显像及VEGF表达在
非小细胞肺癌预后评估中的价值[J]. 中国临床医学影像杂志, 2019, 30(3): 174-178.
ZHOU Xiao-liang1, DENG Hao-yu2, WU Wu-lin1, MO Yi3, LOU Ming-wu1. Prognostic value of 18F-FDG PET/CT imaging and VEGF expression in non-small cell lung cancer. JOURNAL OF CHINA MEDICAL IMAGING, 2019, 30(3): 174-178.
[1]Al-Shahrabani F, Vallbhmer D, Angenendt S, et al. Surgical strategies in the therapy of non-small cell lung cancer[J]. World J Clin Oncol, 2014, 5(4): 595-603.
[2]Volpi S, Ali JM, Tasker A, et al. The role of positron emission tomography in the diagnosis, staging and response assessment of non-small cell lung cancer[J]. Ann Transl Med, 2018, 6(5): 95.
[3]李艳，代永亮，段小艺，等. 肺癌18F-FDG PET/CT的SUV、淋巴结转移及远处转移的分析[J]. 实用放射学杂志，2013，29（11）：1762-1765.
[4]杨桂芬，朱虹. 第7版肺癌TNM分期及影像学在其评估中的价值[J]. 放射学实践，2012，27（7）：803-806.
[5]Matern J, Koomagi R, Volm M. Vascular endothelial growth factor experssion angiogenesis in non-small cell lung carcinomas[J]. Int J Oncol, 1995, 6(5): 1059-1062.
[6]Suzawa N, Ito M, Qiao S, et al. Assessment of factors influencing FDG uptake in non-small cell lung cancer on PET/CT by investigating histological differences in expression of glucose transporters 1 and 3 and tumor size[J]. Lung Cancer, 2011, 72(2): 191-198.
[7]Thie JA, Smith GT, Hubner KF, et al. 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography sensitivity to serum glucose: a survey and diagnostic applications[J]. Mol Imaging Biol, 2005, 9(5): 361-368.
[8]Zhang H, Wroblewski K, Liao S, et al. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer[J]. Acad Radiol, 2013, 20(1): 32-40.
[9]Stiles BM, Nasar A, Mirza F, et al. Ratio of positron emission tomography uptake to tumor size in surgically resected non-small cell lung cancer[J]. Ann Thorac Surg, 2013, 95(2): 397-403; 404.
[10]Deryugina EI. Chorioallantoic membrane microtumor model to study the mechanisms of tumor angiogenesis, vascular permeability, and tumor cell intravasation[J]. Methods Mol Biol, 2016, 1430: 283-298.
[11]Pomme G, Augustin F, Fiegl M, et al. Detailed assessment of microvasculature markers in non-small cell lung cancer reveals potentially clinically relevant characteristics[J]. Virchows Arch, 2015, 467(1): 55-66.
[12]Seto T, Higashiyama M, Funai H, et al. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage Ⅰ non-small-cell lung cancer[J]. Lung Cancer, 2006, 53(1): 91-96.
[13]Tabone MD, Brugières L, Piperno-Neumann S, et al. Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study[J]. BMC Cancer, 2017, 17(1): 419.
[14]Tas F, Duranyildiz D, Oguz H, et al. Serum vascular endothelial growth factor(VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer[J]. Cancer Invest, 2006, 24(6): 576-580.
[15]Ohta Y, Tanaka Y, Watanabe G, et al. Predicting recurrence following curative surgery in stage Ⅰ non-small cell lung cancer patients using an angiogenesis-associated factor[J]. J Exp Clin Cancer Res, 2007, 26(3): 301-305.
[16]周晓亮，邓豪余，李新辉，等. 18F-FDG PET/CT显像与血清VEGF水平诊断非小细胞肺癌[J]. 中国医学影像技术，2014，30（9）：1028-1031.
[17]Bille A, Okiror L, Skanjeti A, et al. The prognostic significance of maximum standardized uptake value of primary tumor in surgically treated non-small cell lung cancer patients: analysis of 413 cases[J]. Clin Lung Cancer, 2013, 14(2): 149-156.
[18]Higashi K, Ueda Y, Arisaka Y, et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer[J]. J Nucl Med, 2002, 43(1): 39-45.
